

July 27, 2018

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrp code: 532983

Dear Sirs,

Sub: Unaudited Financial Results for the quarter ended June 30, 2018

Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter ended June 30, 2018 which were approved by the Board of Directors of the Company, at its meeting held on July 27, 2018 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 12.30 p.m. and concluded at 2.45 p.m.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head – Legal & Company Secretary



Encl: As above

Limited review report on unaudited Financial Results of RPG Life Sciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors of
RPG Life Sciences Limited**


We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 30 June 2018 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the 3 months ended 31 March 2018 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W/W-100022



Bhavesh Dhupelia
Partner
Membership No: 042070

Mumbai
27 July 2018

(Rs. in Lakhs)				
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018				
Particulars	3 months ended			Year ended
	30-06-2018	31-03-2018	30-06-2017	31-03-2018
	Unaudited	Audited (Refer Note 2)	Unaudited	Audited
1 Revenue from Operations	7,989	8,346	7,851	34,714
2 Other Income	39	32	9	98
3 Total Income	8,028	8,378	7,860	34,812
4 Expenses				
(a) Cost of Materials Consumed	1,511	2,237	1,458	7,195
(b) Purchases of Stock-in-Trade	1,215	1,364	1,006	4,935
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(250)	(852)	(179)	(669)
(d) Excise Duty Paid on sale of goods	-	-	319	319
(e) Employee Benefits Expense	2,222	2,487	2,042	9,014
(f) Finance Costs	104	83	96	380
(g) Depreciation and Amortisation Expense	371	368	348	1,434
(h) Other Expenses	2,597	2,252	2,723	10,168
Total Expenses	7,770	7,939	7,813	32,776
5 Profit before tax	258	439	47	2,036
6 Income tax expenses				
a. Current Tax	61	88	10	385
b. Deferred Tax	14	226	(6)	306
7 Profit for the period	183	125	43	1,345
8 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	(6)	47	(23)	(22)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	8	-	8
Other Comprehensive Income Net of Tax	(4)	55	(23)	(14)
9 Total Comprehensive Income for the period	179	180	20	1,331
10 Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323
11 Other Equity				14,152
12 Earnings per Share (of Rs. 8 each) (not annualised):				
(a) Basic	1.11	0.76	0.26	8.13
(b) Diluted	1.11	0.76	0.26	8.13

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 27, 2018. The Statutory Auditors of the Company have conducted a 'Limited Review' of the results for the quarter ended June 30, 2018.
- The figures for the quarter ended March 31, 2018 are the balancing figures between the audited financial results for the year ended March 31, 2018 and the published unaudited financial results for the nine months ended December 31, 2017 which were subjected to a limited review.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- With effect from July 1, 2017, Goods and Service Tax ("GST") has been implemented which has replaced several indirect taxes including excise duty. While Ind AS required excise duty to be included in revenues, GST is required to be excluded from revenue. Consequently the revenue from operations for the quarters ended March 31, 2018 and June 30, 2018 are reported net of GST. However revenue for all other periods presented is inclusive of excise duty, where applicable. The Net Revenue from operations (Net of GST/Excise Duty) as applicable are stated below:

Particulars	3 months ended			Year ended
	30-06-2018	31-03-2018	30-06-2017	31-03-2018
Revenue from Operations	7,989	8,346	7,851	34,714
Less: Excise Duty	-	-	319	319
Net Revenue from operations	7,989	8,346	7,532	34,395

- Effective April 1, 2018, the Company has adopted Ind AS 115 'Revenue from contracts with customers'. Based on the assessment done by the management, there is no material impact on the revenue recognised during the period.

For RPG Life Sciences Limited



RK

CT. Renganathan
 Managing Director
 DIN : 02158397
 Mumbai, July 27, 2018